O
Obat
Invoicing software for contractors and self-employed - construction sector
About Obat
Obat.fr is a French startup that provides a comprehensive digital platform for building professionals. The company's primary market is the construction industry, serving over 15,000 professionals, including independent contractors, small businesses, and larger construction firms.
Read full description
Obat.fr's platform offers a range of services designed to streamline operations and improve profitability. These include the ability to quickly and easily generate quotes and invoices that are legally compliant, with automatic inclusion of more than 19 legal notices. This feature is particularly important given the strict regulatory environment in which construction businesses operate.
The platform also includes tools for project management, such as scheduling and resource allocation. These features allow users to plan their construction projects, manage their teams, and monitor progress. The platform is mobile-friendly, making it easy for users to access these tools while on the go.
In addition, Obat.fr offers a library of construction tasks, complete with detailed descriptions, supply lists, labor time, and pricing. This feature helps users accurately estimate costs, which can be a challenging aspect of running a construction business.
Obat.fr operates on a subscription-based business model, offering a 14-day free trial to attract new users. The company also provides free support and guidance, even before a business is established, further enhancing its value proposition.
In summary, Obat.fr is a comprehensive digital solution for construction professionals, offering tools for quotation, invoicing, project management, and cost estimation. Its user-friendly platform and commitment to staying abreast of regulatory changes make it a valuable partner for businesses in the construction industry.
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2023 | $13M | $53M | Holnest · Evolem · Crédit Mutuel Equity · Truffle Capital | ↗ |
| SEED✓Equity / VC | Sep 2022 | $6.6M | $26M | Holnest · Evolem · Truffle Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Obat is 420K monthly website visits, up 7.7% over the last three months. Obat's team grew 14.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Holnest
Evolem
Truffle Capital
Series A6 investors entered at this stage
Crédit Mutuel Equity
Arthur Waller
Crédit Mutuel Innovation
Kima Ventures
NewAlpha Asset Management
NCI
Other known investors4 additional known investors
Courtin Investment
ISAI Gestion
Manuel Jaffrin
Normandie Capital Investissement
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Obat on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Obat’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.





